Asset Management, Lp Chen B... Net Worth

The estimated Net Worth of Asset Management, Lp Chen B... is at least $237 millió dollars as of 14 May 2019. Asset B owns over 23,268 units of Turning Point Therapeutics Inc stock worth over $237,331,116 and over the last 6 years Asset sold TPTX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Asset B TPTX stock SEC Form 4 insiders trading

Asset has made over 2 trades of the Turning Point Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Asset exercised 23,268 units of TPTX stock worth $50,957 on 14 May 2019.

The largest trade Asset's ever made was buying 400,000 units of Turning Point Therapeutics Inc stock on 22 April 2019 worth over $7,200,000. On average, Asset trades about 141,089 units every 7 days since 2019. As of 14 May 2019 Asset still owns at least 3,122,367 units of Turning Point Therapeutics Inc stock.

You can see the complete history of Asset B stock trades at the bottom of the page.

Insiders trading at Turning Point Therapeutics Inc

Over the last 6 years, insiders at Turning Point Therapeutics Inc have traded over $45,947,838 worth of Turning Point Therapeutics Inc stock and bought 2,385,408 units worth $60,168,920 . The most active insiders traders include Plc Gsk, Patrick Machado és Advisors Llc Orbi Med Capit.... On average, Turning Point Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $4,727,594. The most recent stock trade was executed by Paolo Tombesi on 27 July 2022, trading 1,183 units of TPTX stock currently worth $88,654.

What does Turning Point Therapeutics Inc do?

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor currently pending IND submission. Turning Point's next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.

Complete history of Asset B stock trades at Turning Point Therapeutics Inc

Turning Point Therapeutics Inc executives and stock owners

Turning Point Therapeutics Inc executives and other stock owners filed with the SEC include:

• Yi Larson,
  Chief Financial Officer, Executive Vice President
• Mohammad Hirmand,
  Executive Vice President, Chief Medical Officer
• Annette North,
  Executive Vice President, General Counsel, Secretary
• Dr. Athena Maria Countouriotis M.D.,
  Pres, CEO & Director
• Andrew John Partridge,
  Exec. VP & Chief Commercial Officer
• Carol Gallagher,
  Independent Director
• Dr. Mohammad Hirmand,
  Exec. VP & Chief Medical Officer
• Patrick Machado,
  Independent Director
• Annette C. North Esq., LLB,
  Exec. VP, Gen. Counsel & Company Sec.
• Dr. Siegfried Reich Ph.D.,
  Exec. VP & Chief Scientific Officer
• Simeon George,
  Independent Director
• Sheila Gujrathi,
  Chairman of the Board
• Jacob Chacko,
  Independent Director
• Jim Mazzola,
  IR Contact Officer
• Garry Nicholson,
  Independent Director
• Heather Adams,
  Vice President of Human Resources
• Brian Baker,
  Vice President - Finance and Administration
• Siegfried Reich,
  Executive Vice President, Chief Scientific Officer
• Athena Countouriotis,
  President, Chief Executive Officer, Director
• Dr. Jeffrey P. Whitten,
  Sr. VP of Pre-Clinical Devel.
• Brian Sun J.D., M.S.,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Dr. Gavin Hirst Ph.D.,
  Sr. VP of Chemistry & Interim Chief Scientific Officer
• Raymond J. Furey J.D.,
  Sr. VP & Chief Compliance Officer
• Dr. Adam D. Levy M.B.A., Ph.D.,
  Sr. VP of Investor Relations & Corp. Communications
• Ed Gemo,
  Sr. VP & Chief Information Officer
• Kyri K. Van Hoose,
  VP of Accounting & Interim Principal Accounting Officer
• Paolo Tombesi,
  Exec. VP & CFO
• Jingrong Jean Cui,
  Director
• Plc Gsk,
  Director
• Hongbo Lu,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Asset Management, Lp Chen B...,
  
• Carl L Gordon,
  Director
• Barbara W. Bodem,
  Director
• Mark J Alles,
  Director
• Paolo Tombesi,
  EVP & Chief Financial Officer
• Brian Sun,
  SVP & General Counsel
• Steve M Sabus,
  SVP & Chief Commercial Officer